Rodabe N. Amaria
0000-0001-6876-278X
Publication & Citation Trends
Most Cited Works
Publications
318 total
Abstract LB-A010: Translational data validate OBX-115 mechanism of action: Impact of dosing on clinical outcome in advanced (adv) melanoma
Cited by 0
Semantic Scholar
Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal Dissection.
Cited by 0
Semantic Scholar
Abstract 3721: Anti-tumor function and long-term persistence of KSQ-001EX, a SOCS1-edited eTIL® therapy, independent of IL-2 co-administration
Cited by 0
Semantic Scholar
Phase 1/2 dose escalation/expansion study of REGN10597 (anti–PD-1–IL2Rα-IL2) in patients with advanced solid tumors.
Cited by 0
Semantic Scholar
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.
Cited by 11
Semantic Scholar
A phase 1/2 study of KSQ-004EX: Autologous tumor infiltrating lymphocytes, engineered to inactivate genes encoding SOCS1 and Regnase-1, in patients with select advanced solid tumors.
Cited by 1
Semantic Scholar
OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mbIL15) in patients (pts) with immune checkpoint inhibitor (ICI)–resistant advanced melanoma: Phase 1 results of the Agni-01 multicenter study.
Cited by 3
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(132)
CAR-T cell therapy research
(94)
Melanoma and MAPK Pathways
(83)
Immunotherapy and Immune Responses
(68)
Cutaneous Melanoma Detection and Management
(53)
Frequent Co-Authors
Affiliations
The University of Texas MD Anderson Cancer Center
The Medical Center of Aurora
Weatherford College
Sanofi (France)
University of Colorado Health